Alenphosome™ – Alendronate Liposomes (Neutral) (F70103A-N)

Description

Alenphosome™ – Alendronate Liposomes (Neutral)

Specifications

Active: alendronate sodium (CAS 121268-17-5), 5.0 mg/mL

Volume: 2.0 mL

Lipid composition: phosphatidylcholine and cholesterol

Internal/External solution: phosphate buffered saline (20mM sodium phosphate, 09wt% NaCl), pH 7.0 – 7.5

Usage: warm to room temperature and mix well before use.

Dosage: this is a new product and no recommended dose is available at this point.

Additional information

SIZE (ml)	2 ML

1. Benjamin J. Burwitz et al. Technical Advance: Liposomal alendronate depletes monocytes and macrophages in the nonhuman primate model of human disease. J Leukoc Biol. 2014 Sep; 96(3): 491–501. PMC4632165
2. Renate Frei, Comparison of cytotoxic properties of free and liposomal bisphosphonates in vitro (Diploma Thesis) (Link)
3. Mönkkönen J, van Rooijen N, Ylitalo P., Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice. Pharmacol Toxicol. 1991 Apr;68(4):284-6. (Link)
4. Makkonen N, Hirvonen MR, Teräväinen T, Savolainen K, Mönkkönen J., Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. J Pharmacol Exp Ther. 1996 May;277(2):1097-102 (link)
5. van Rooijen N, Kors N. Effects of intracellular diphosphonates on cells of the mononuclear phagocyte system: in vivo effects of liposome-encapsulated diphosphonates on different macrophage subpopulations in the spleen. Calcif Tissue Int. 1989 Sep;45(3):153-6. (Link)
6. Epstein H. et al., Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization. AAPS J. 2008 Dec;10(4):505-15. Epub 2008 Oct 21. (Link)